Experience

• 

  Novartis

  Sept 1997 - Jun 2004

  Preclinical neuropharmacology research group leader

  Pam worked in a team that discovered new targets (receptors/channels) for the treatment of chronic pain. Pam was a team leader for a neuropharmacology lab with 5 direct reports, providing high through-put assay screening service for the optimisation of compounds in developement for the treatment of chronic pain. Specifically, Pam initiated highly fruitful multidisciplinary international (Europe, USA, Japan) functional genomics research programme resulting in 11 patents applications and one mature target with compounds in development for the treatment of Chronic Pain; developed the first ever application of novel siRNA technology for validation of new genomic targets in rodent models of chronic pain; was a significant author on thirteen scientific peer reviewed publications; was promoted 3 times in 7 years (Research Scientist I, II, III); successfully co-supervision of PhD student on a Medical Research Council Industrial Studentship Programme with Professor A. Cass (Imperial College, London). Show less

• 

  Bristol-myers squibb

  Jun 2004 - Apr 2008

  Neuroscience medical affairs advisor

  Over the 4 years in BMS, Pam was promoted from a Medical Science Liaison (MSL) to a Senior Medical Affairs Advisor. As an MSL, Pam secured 4 successful formulary applications for a psychiatric product Abilify (aripiprazole), managed Key Opinion Leader plan and disseminated key medical information, mentored new Neuroscience MSL recruits & designing and co-ordinating their induction training course, identied and supported investigator Sites for post marketing clinical trials; identified and evaluated Investigator Lead Study proposals.As Medical Advisor, Pam provided medical support to the UK Brand Team. Specifically, Pam developed and managed a UK publication plan, working with an editorial agency; developed & co-ordinated disease & product area training of Neuroscience MSL team, developed programmes for satellite symposia at international and national congresses in conjunction with Medical Education agency; developed and co-chaired National & Regional Advisory Boards on Bipolar Disorder & Schizophrenia , provided medical input into development of Advanced Budget Notification Programme for Healthcare Managers; developed UK Medical Plan for AbilifyFor the last 6 months, Pam was seconded to the European business in Paris to lead the European publication and congress planning activities for Abilify, and to develop the MSLstrategy and their presentation materials Show less

• 

  Eisai

  Apr 2008 - May 2015

  Executive director, global brand lead, halaven - oncology

  Pam Ganju, PhD, is an Executive Director in the Eisai Global Oncology Business Unit. Pam is the Global Brand Leader for Halaven (eribulin) a novel chemotherapy agent indicated for metastastic breast cancer that has been approved in over 50 countries world-wide. She is based in Eisai’s EMEA headquarters in the U.K.Pam is accountable for Halaven's Annual Global Business Plan in metastatic breast cancer as well as for developing global launch excellence for Halaven's future indications. Pam joined Eisai in 2008 as the Medico-Marketing Manager for the Critical Care Franchise for Eisai Europe after which she became the Head of Marketing for the EMEA Oncology Business Unit where she helped launch Halaven in 2011. Show less

• 

  Eisai emea

  May 2015 - now

  • Vice President, Oncology Alliance Management, EMEA and Business Unit Director, UK & IRE

    Apr 2021 - now

  • Vice President - Global Brand Leader, Halaven; & EMEA Oncology Marketing Director

    May 2015 - Apr 2021
• 

  Eisai europe limited

  Jun 2018 - Apr 2021

  Vice president, emea marketing & business unit director oncology, uk & roi